Christopher Jackson has divided his career between the pharmaceutical industry and academia, focussing throughout on the pathophysiology and treatment of cardiovascular disease. He was awarded his Ph.D. degree in 1989 at the University of Cambridge, Cambridge, UK, for work carried out at Cambridge and at Aventis on factors and drugs, particularly antihypertensive agents controlling the behaviour of vascular smooth muscle cells after arterial injury. He extended this work in the laboratory of Michael Reidy at the University of Washington in Seattle, Wash, USA, showing that PDGF and FGF-2 are controlling factors for smooth muscle cell migration and that plasminogen activators form a link between fibrinolysis and arterial repair. After a period in pharmaceutical research at Pfizer and DuPont Merck in the UK and the USA, he returned to academia to head a research group at the Bristol Heart Institute in the University of Bristol, Bristol, UK investigating atherosclerotic plaque rupture. This led to the development of the first animal model of plaque rupture and has shown that a number of proteolytic enzymes are coordinated during plaque rupture and subsequent repair. More recently, they have been investigating links between arterial adaptive remodelling and plaque rupture.
Biography Updated on 12 January 2011